id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S10173 R37190 |
Blotière (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 | Cleft lip with or without cleft palate | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
8.74 [1.46;52.44] C excluded (control group) |
3/517 2/2,997 | 5 | 517 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10048 R36441 |
Blotière (Topiramate) (Controls unexposed NOS) (Mixed indications), 2019 | Cleft lip with or without cleft palate | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 6.80 [1.40;20.00] | 3/517 1,637/1,875,733 | 1,640 | 517 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8616 R28777 |
Mines (Topiramate) (Other indications), 2014 | Cleft lip with or without cleft palate | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: No | 2.80 [1.00;7.90] | 5/1,745 14/13,512 | 19 | 1,745 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10298 R37724 |
Vajda (Topiramate) (Controls unexposed, sick), 2013 | Palate/lip malformation | at least 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 3.37 [0.07;172.23] C | 0/44 0/147 | 0 | 44 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8568 R28503 |
Margulis (Topiramate) (Mixed indication), 2012 | Cleft lip with or without cleft palate | 1st trimester | case control | unexposed (general population or NOS) | Adjustment: No Matched | 5.36 [1.49;20.07] | 7/13 3,034/18,401 | 3,041 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 4.24 [2.15;8.38] | 4,700 | 2,319 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Topiramate) (Controls unexposed NOS) (Mixed indications; 2: Topiramate) (Other indications; 3: Topiramate) (Controls unexposed, sick; 4: Topiramate) (Mixed indication;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 10173